Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine

BACKGROUND: To meet the demand for effective and affordable inactivated polio vaccines (IPVs), a reduced dose, aluminium hydroxide (Al(OH)(3))-adjuvanted IPV vaccine was developed (IPV-Al, Picovax®) and evaluated in clinical trials. The present trial is an extension of two previous trials (a primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Sáez-Llorens, Xavier, Chan, Milagros, DeAntonio, Rodrigo, Petersen, Torben, Olesen, Charlotte, Jensen, Jens Søndergaard, Sørensen, Charlotte, Ekstrand, Lena Messerschmidt, Czort, Michaela Katrine, Kristensen, Hans-Henrik, Thulstrup, Niels, Christoffersen, Dorte Birk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488130/
https://www.ncbi.nlm.nih.gov/pubmed/36064670
http://dx.doi.org/10.1016/j.vaccine.2022.06.084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488130/
https://www.ncbi.nlm.nih.gov/pubmed/36064670
http://dx.doi.org/10.1016/j.vaccine.2022.06.084

Ejemplares similares